Biomaxima (FRA:944) Accounts Payable: €1.15 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:944 Biomaxima SA FRA:944
51 GF Score
Price €1.96
GF Value €2.97
! 4 Warning Signs
View Full Analysis

What is Biomaxima Accounts Payable?

Biomaxima FRA:944 -0.61% 51 Accounts Payable is €1.15 Mil as of Mar. 2026. GuruFocus rates FRA:944 with a GF Score™ of 51/100 and a GF Value™ of €2.97. The stock has 4 warning signs investors should review.

Biomaxima's Accounts Payable for the quarter that ended in Mar. 2026 was €1.15 Mil.

Biomaxima's quarterly Accounts Payable increased from Sep. 2025 (€1.10 Mil) to Dec. 2025 (€1.13 Mil) and increased from Dec. 2025 (€1.13 Mil) to Mar. 2026 (€1.15 Mil).

Biomaxima's annual Accounts Payable increased from Dec. 2023 (€0.79 Mil) to Dec. 2024 (€0.97 Mil) and increased from Dec. 2024 (€0.97 Mil) to Dec. 2025 (€1.13 Mil).

Biomaxima Accounts Payable Historical Data

* Premium members only.

The historical data trend for Biomaxima's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomaxima Accounts Payable Chart

Biomaxima Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.01 0.88 0.79 0.97 1.13

Biomaxima Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 1.08 1.10 1.13 1.15
FRA:944
51GF Score
Biomaxima SA FRA:944
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomaxima Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €1.15 Mil mean?
Biomaxima (FRA:944) has a Accounts Payable of €1.15 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Biomaxima and its competitors.
Is Biomaxima's Accounts Payable too high?
Biomaxima's current Accounts Payable is €1.15 Mil. Overall, Biomaxima has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Biomaxima's Accounts Payable compare to TMO and DHR?
Biomaxima's Accounts Payable of €1.15 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Diagnostics & Research company?
A good Accounts Payable depends on the Medical Diagnostics & Research industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Biomaxima and its competitors. Biomaxima's current Accounts Payable is €1.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomaxima stock overvalued right now?
Biomaxima (FRA:944) has a current Accounts Payable of €1.15 Mil. The stock's GF Value™ is €2.97, compared to a current price of €1.96 — trading 34.1% below its estimated fair value. The current Accounts Payable is €1.15 Mil. Biomaxima's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Biomaxima (FRA:944), the current Accounts Payable is €1.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biomaxima (FRA:944) Overvalued in 2026?

Based on GuruFocus' analysis, Biomaxima stock appears to be undervalued. The current stock price of €1.96 is trading 34.1% below its estimated GF Value™ of €2.97.

Key valuation signals for FRA:944:

  • Accounts Payable: €1.15 Mil
  • GF Value™: €2.97 vs. price of €1.96 (34.1% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the FRA:944 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biomaxima Business Description

Other Exchanges BMX:Poland
Address 5 Vetterow Street, Lublin, POL, 20-277
BioMaxima SA is a Polish company operating in the market of laboratory diagnostics. It is a manufacturer of microbiological substrates as well as a wide range of reagents and diagnostic equipment. The company is also a distributor of products of recognized multinational diagnostic companies such as: Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe and Biolog.
51GF Score

Get the complete analysis for FRA:944

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.96
Price
€2.97
GF Value